Navigation Links
Angiotech announces positive results from Bio-Seal(TM) clinical study
Date:3/9/2009

or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and ot
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and NEW YORK CITY and ... As a leading provider of market research reports and solutions, ... LLC, indicating that 2015 will be a year of market ... For executives operating a stem cell company or cord blood ... task. You must analyze market conditions, predict industry trends, and ...
(Date:4/1/2015)... 01, 2015 Earlier this year, ... life sciences industry association that represents research-based life science ... , Jonathan Parker, AJO’s Vice President of Business Development ... February, an event that attracted over 750 attendees. ... a 73 year old cancer survivor shared his moving ...
(Date:4/1/2015)... 2015 Immunocore Limited ("the ... drugs to treat cancer, viral infections and autoimmune ... of Christina Coughlin as Chief Medical ... medical and regulatory leadership to the pre-clinical and ... Coughlin has extensive experience in oncology drug development, ...
(Date:3/31/2015)... 2015  Biotest Pharmaceuticals Corporation (BPC), a leading developer ... addition of its newest plasma collection center located at ... Arkansas . The over 16,000 square foot state-of-the-art ... 26 th 2015 and brings the total number ... "This facility represents another milestone in our continued ...
Breaking Biology Technology:MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2
... THOROLD, ON, Oct. 15 /PRNewswire/ - Norgen Biotek ... advancing powerful,tools for nucleic acids and protein purification, ... the isolation of nucleic acids from,environmental samples, the ... Kit. These kits are ideal for environmental microbiological,studies, ...
... Baxa is promoting its new PadLock Set Saver product ... Salt Lake City,UT, at The Salt Palace, October 15-17, ... is promoting,its new PadLock Set Saver at the ANCC ... aseptic IV administration set storage,solution, PadLock provides a secure ...
... OLDSMAR, Fla., Oct. 15 Cryo-Cell,International, Inc. (OTC ... largest and most established family cord blood banks, ... months ended August 31,2008., Consolidated revenues for ... approximately $4.6 million for the third quarter of,2007. ...
Cached Biology Technology:High-quality DNA/RNA from Microorganisms in Environmental Samples 2Baxa Corporation Features PadLock(R) Set Saver at the ANCC National Magnet Conference(TM) 2Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 2Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 3Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 4Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 5Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 6
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... 2013 Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ), ... the medical and retail industries, announced that their patented software ... means to meet the priorities spelled out by the US ... United States Attorneys titled, "Guidance Regarding Marijuana ...
... flatworms have the remarkable ability to regrow any missing body ... the molecular basis of regeneration. Over the ... differ depending on the severity of the injury they suffer. ... wound reacts at the cellular and molecular levels quite differently ...
... to the origin of species as "that mystery of mysteries," ... cannot fully explain how new animals and plants arise. ... based on the assumption that the main cause of the ... formation of barriers to reproduction between populations. Those barriers ...
Cached Biology News:Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 2Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 3Tissue loss triggers regeneration in planarian flatworms 2Long-held assumption about emergence of new species questioned 2Long-held assumption about emergence of new species questioned 3
... The H2OBIT is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. ,A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
... RNase ONE Ribonuclease is a 27kDa ... the degradation of RNA to cyclic nucleotide ... the degradation of these intermediates to 3-NMPs ... the few known RNases that can cleave ...
... polyclonal to Dideoxycytidine Dideoxycytidine is a cytidine ... in inhibiting retroviral activity. Immunogen: ... Specificity: The specificity of the ddC ... the moles of ddC to moles of ddC ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: